Bildkälla: Stockfoto

Scandion Oncology Q2 2021: Progress in the making - Redeye

Redeye comments on Scandion’s Q2‘21 report, following an eventful quarter. Towards the end of Q2, Scandion presented promising CORIST phase II dose-finding data. We are encouraged by the company’s progress and reiterate our Base Case at SEK 24 per share.

Redeye comments on Scandion’s Q2‘21 report, following an eventful quarter. Towards the end of Q2, Scandion presented promising CORIST phase II dose-finding data. We are encouraged by the company’s progress and reiterate our Base Case at SEK 24 per share.
Börsvärldens nyhetsbrev
ANNONSER